ERK
ERK is a key protein in the MAPK (Mitogen-Activated Protein Kinase) signaling pathway, which is involved in transmitting signals from cell surface receptors to the DNA in the cell nucleus. ERK plays a crucial role in the regulation of various cellular processes, including proliferation, differentiation, and survival. Dysregulation of ERK signaling is associated with the development of cancer and other diseases, making it an important target for therapeutic intervention. At CymitQuimica, we offer a selection of high-quality ERK inhibitors and modulators to support your research in cell signaling, oncology, and therapeutic development.
Found 217 products of "ERK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
DOR agonist 2
CAS:Compound 3 (DOR agonist 2) acts as a Delta Opioid Receptor agonist. It inhibits the expression of TNF-α, obstructs NF-κB transportation to the nucleus, and activates the G protein-mediated ERK1/2 pathway. This compound is useful for research into neurodegenerative diseases.Formula:C29H26N2O3Color and Shape:SolidMolecular weight:450.53MAP855
CAS:MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97ATX inhibitor 26
CAS:ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30Hypothemycin
CAS:Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formula:C19H22O8Purity:98%Color and Shape:SolidMolecular weight:378.37KRASG12C IN-15
CAS:KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.Formula:C31H32FN3O2Color and Shape:SolidMolecular weight:497.603SOS1 activator 2
CAS:SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.Formula:C26H28ClFN6Color and Shape:SolidMolecular weight:478.992SHR2415
SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.Formula:C23H22ClN7O2Color and Shape:SolidMolecular weight:463.92KRAS inhibitor-27
CAS:KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106ERK-IN-2
CAS:ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].Formula:C16H18ClN5O2Purity:98%Color and Shape:SolidMolecular weight:347.80ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01AL 8810
CAS:AL-8810 is an 11β-fluoro analog of PGF 2α with selective antagonist effects at the PGF 2α receptor (FP receptor) [1].Formula:C24H31FO4Color and Shape:SolidMolecular weight:402.5(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Formula:C27H30FN5O5SColor and Shape:SolidMolecular weight:555.63Rineterkib
CAS:Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.Formula:C26H27BrF3N5O2Purity:99.73%Color and Shape:SolidMolecular weight:578.42Ref: TM-T11224
1mg87.00€5mg170.00€1mL*10mM (DMSO)224.00€10mg318.00€25mg538.00€50mg765.00€100mg1,035.00€Ravoxertinib hydrochloride
CAS:Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).Formula:C21H19Cl2FN6O2Purity:98%Color and Shape:SolidMolecular weight:477.32Omtriptolide
CAS:Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.Formula:C24H28O9Purity:98%Color and Shape:SolidMolecular weight:460.479Pamoic acid
CAS:Pamoic acid is the orphan G protein-coupled receptor GPR35 agonist. Pamoic acid activates ERK and beta-arrestin2 and causes antinociceptive activity.
Formula:C23H16O6Purity:99.99%Color and Shape:Fine Yellow PowderMolecular weight:388.37WQ-C-401
CAS:WQ-C-401 is an orally active inhibitor of the platelet-derived growth factor receptor (PDGFR). It inhibits cell proliferation by blocking PDGFR auto-phosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRαY849 and 5.8 nM for PDGFRβY1021. Additionally, WQ-C-401 suppresses the proliferation and migration of PASMCs by inhibiting PDGF-BB-induced phosphorylation of ERK1/2, reduces collagen I synthesis, and increases α-SMA expression, thereby preventing pulmonary vascular remodeling. This compound shows promise for research in the field of pulmonary arterial hypertension.
Formula:C24H26N4O3Color and Shape:SolidMolecular weight:418.49Ref: TM-T200766
Discontinued product
